Cargando…
Cardioprotecive Properties of Known Agents in Rat Ischemia-Reperfusion Model Under Clinically Relevant Conditions: Only the NAD Precursor Nicotinamide Riboside Reduces Infarct Size in Presence of Fentanyl, Midazolam and Cangrelor, but Not Propofol
Background: Cardioprotective strategies against ischemia-reperfusion injury (IRI) that remain effective in the clinical arena need to be developed. Therefore, maintained efficacy of cardioprotective strategies in the presence of drugs routinely used clinically (e.g., opiates, benzodiazepines, P2Y(12...
Autores principales: | Xiao, Yang, Phelp, Philippa, Wang, Qian, Bakker, Diane, Nederlof, Rianne, Hollmann, Markus W., Zuurbier, Coert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8435675/ https://www.ncbi.nlm.nih.gov/pubmed/34527711 http://dx.doi.org/10.3389/fcvm.2021.712478 |
Ejemplares similares
-
Nicotinamide Riboside and Dihydronicotinic Acid Riboside Synergistically Increase Intracellular NAD(+) by Generating Dihydronicotinamide Riboside
por: Ciarlo, Eleonora, et al.
Publicado: (2022) -
The emergence of the nicotinamide riboside kinases in the regulation of NAD(+) metabolism
por: Fletcher, Rachel S, et al.
Publicado: (2018) -
Nicotinamide Riboside Kinase Structures Reveal New Pathways to NAD(+)
por: Tempel, Wolfram, et al.
Publicado: (2007) -
The NAD(+) precursor nicotinamide riboside decreases exercise performance in rats
por: Kourtzidis, Ioannis A., et al.
Publicado: (2016) -
Balancing NAD(+) deficits with nicotinamide riboside: therapeutic possibilities and limitations
por: Cercillieux, Angelique, et al.
Publicado: (2022)